PRAX Praxis Precision Medicines, Inc. Insider Trading

Principal Accounting Officer Mastrocola sells 13,600 shares at $191.96–$192.71 for $2.6M; retains 10.4K shares post-sale

Mastrocola executed 2 separate sales totaling 13,600 shares for $2,612,243.99, reducing her holdings by 56.6% to 10,441 shares. The sales occurred at a blended average price of $192.08, near the company's 52-week high of $201.00, with the current price at $169.80 reflecting a -15.5% decline from peak. Praxis is unprofitable with latest quarterly revenue of $0.00 and a net loss of $-73,934,000.00, though it reported annual revenue growth of +249.5%. The timing of a major insider share reduction by the Principal Accounting Officer at near-peak prices—given the company's cash-burn profile and lack of current revenue generation—warrants scrutiny of the firm's path to profitability and whether this sale reflects confidence constraints at the current valuation.

General Counsel Nemiroff sells 25,130 shares at avg $193.09 for $4.9M, reducing stake by 54.7%, stock now -15.5% from 52-week high.

Nemiroff Alex, General Counsel and Secretary, executed 4 separate sales totaling 25,130 shares for $4,852,255.51 on 2025-11-20, disposing of 54.7% of his pre-transaction holdings and retaining 20,831 shares. The blended average transaction price was $193.09, while the current price stands at $169.80, representing a 12.0% decline from his sale price and placing the stock 15.5% below its 52-week high. The company is unprofitable with net income of $-73,934,000.00 over its most recent full fiscal year and zero quarterly revenue, though it posted 249.5% annual revenue growth. His prior trade at PRAX (a November 2024 sell) was followed by a 90-day gain of 6.5%, indicating his historical sales at this ticker have not been well-timed. This large divestiture occurs as the stock pulls back significantly from recent highs, warranting examination of whether his timing reflects operational or valuation concerns.

Adage Capital (10% owner) sells 313,910 shares totaling $33.2M across 10 transactions on 2025-10-16

Adage Capital Management filed 10 separate sales totaling 313,910 shares (313.9K shares) for $33,198,123.57 ($33.2M), reducing its stake from 2,374,085 shares (2.37M shares) to 2,060,175 shares (2.06M shares), a reduction of 13.2%. The transaction prices ranged from $90.00 to $140.00 per share with a blended average of $105.76, while the current stock price stands at $189.99, indicating the stock has appreciated significantly since the sale dates. Adage remains a substantial 10% owner after the sale, and the company is currently unprofitable with a net income of $-71,127,000.00 ($-71.1M), though it posted annual revenue growth of +249.5%. The filing reveals a material reduction in the insider's position despite the stock's strong recent performance, with the company's fundamentals characterized by high growth but current operating losses.

General Counsel & Secretary sells 8,239 shares of PRAX at $80.20; stock now trading at $71.76, -15.4% from 52-week high.

Nemiroff Alex, General Counsel and Secretary, sold 8,239 shares at $80.20 on 2024-11-14 for $660,827.46, reducing holdings by 44.4% from 18,540 shares to 10,300 shares. The sale occurred near the upper end of the 52-week range ($13.05–$84.83), with the stock currently trading at $71.76, representing a -15.4% decline from the 52-week high. The company is unprofitable, with most recent quarter revenue of $302,000.00 against net income of $-51,910,000.00, and full-year results also showed negative net income. This large proportional reduction in a key officer's position—coupled with the sale at peak valuations and the company's persistent losses—merits investor scrutiny of near-term operational developments and cash runway.